Condition: Gastroesophageal Cancer (GC) · Hepatocellular Carcinoma (HCC) · Endometrial Cancer · Sponsor: Compass Therapeutics
This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.
This description comes directly from the study's public registry record.
Sarah Pilgrim · 617-500-8099 · ctx-10726-001@compasstherapeutics.com
Talia Fountain · 617-500-8099 · ctx-10726-001@compasstherapeutics.com
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
| START New York | Lake Success, New York, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Prisma Health Cancer Institute | Greenville, South Carolina, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07419841